A small molecule inhibitor containing dihydroacridine and its application in inhibiting ornithine decarboxylase (odc)

Abstract

The invention provides a small molecule inhibitor containing dihydroacridine, the small molecule inhibitor is 2,2-dimethyl-N-(6-methyl-4-oxo-3,4-dihydro-2 ‑acridinyl) propionamide, the structural formula is the application of the small molecule inhibitor containing dihydroacridine in inhibiting ornithine decarboxylase (ODC) of the present invention, and the application in the preparation of drugs for treating tumors, and in The application in the preparation of medicines for the treatment of pathogenic microorganism infections has achieved remarkable results.

Description

Technical field[0001]The present invention relates to a small molecule inhibitor of ornithine decarboxylase; ODC, which specifically involves a small molecule inhibitor of human beamine decarboxylase and its application in inhibiting and killing tumor cells.Background technique[0002]Protein is one of the main components of organisms, which is the main substance to complete various life activities. In various proteins, protease is critical to life activities, and almost all biological response processes are catalyzed by proteases. The activity of various proteases in the biology has a strict regulatory mechanism. Once its regulation mechanism has problems, it will cause the corresponding various diseases to cause protease activity, too low or completely inactivation. Therefore, the activity of the protease is regulated by the drug, which has a very important theoretical significance and practical significance to restore and maintain it in a normal level. The structural-based drug des...

AI Technical Summary

Problems solved by technology

However, its binding ability to ODC is weak, and its concentration is very high, and because it is a suicide inhibitor that forms a covalent bond with ODC, its toxic and side effects are very large

Images